Science

A new video from the Harvard Medical School shows the terrifying reality of antibiotic resistance

Read in app

It's no secret: antibiotic resistance has become a growing threat around the world. 

An estimated 23,000 Americans died in 2013 from bacterial infections that didn't respond to antibiotics, and it's getting to the point where gonorrhea may soon become untreatable, and bacteria have even begun developing resistance against antibiotics that are used as last resorts.

To illustrate just how quickly bacteria evolve to develop resistance, researchers at Harvard Medical School set up essentially a huge petri dish.

Screen Shot 2016 09 13 at 9.25.10 AM
Harvard Medical School

They then lined the dish with varying strengths of the antibiotic trimethoprim, starting with a strength that's just a bit stronger than what E. coli could handle. After the bacteria (the white stuff) had a chance to grow in the area without any antibiotics, a mutant starts to appear in the first band of antibiotics. 

first band of resistance
Harvard Medical School

More bacteria continue to mutate and methodically creep their way through the increasing strengths of antibiotics.

more resistance
Harvard Medical School

By the end of the 10 days, the bacteria have mutated their way into a dose of trimethoprim that's 1,000 times stronger than the original dose. 

the most resistance
Harvard Medical School

So the same bugs that at first had a hard time fighting off even just the lowest dose of the antibiotic had in just a little over a week, found a way to make themselves 1,000 times as strong. It's a worrying sign, since developing new antibiotics to tackle mutant bugs is incredibly tricky, and resistance can develop before a drug even gets approved.

Watch the full, terrifying, video

Read next

Lydia was a senior editor for the healthcare team at Insider. She joined Insider in 2015 after graduating from Northwestern University. At Insider, she covered everything from healthcare mega-mergers, to drug-pricing debates, to pharmacy disruptors, to private healthcare startups that rack up high valuations (including Theranos of course), and the new ways people are going to the doctor. That included the changing footprint of the hospital and how they fared in the early months of the coronavirus pandemic.